Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

BRIEF-Aralez says conducted bioequivalence studies comparing Aspirin from old and new suppliers

Published 2016-04-20, 07:18 a/m
© Reuters.  BRIEF-Aralez says conducted bioequivalence studies comparing Aspirin from old and new suppliers
ARLZQ
-

April 20 (Reuters) - Aralez Pharmaceuticals Inc ARZ.TO
* Conducted human bioequivalence studies comparing aspirin
drug manufactured from original aspirin supplier to new primary
aspirin supplier
* Aralez Pharmaceuticals Inc says bioequivalence studies
tested both 81 mg and 325 mg Yosprala doses
* Aralez says study data demonstrated aspirin in Yosprala
formulated from original supplier was bioequivalent to that of
new primary supplier
* Aralez says worked directly with new primary aspirin
supplier to help prepare it for a previously planned inspection
by FDA
* Aralez Pharmaceuticals Inc says FDA inspection has
recently concluded and did not result in any reported compliance
findings

Source text for Eikon: ID:nPn7RfHpQa
Further company coverage: ARZ.TO

(Bengaluru Newsroom: +1 646 223 8780)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.